Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Breast cancer: an up‐to‐date review and future perspectives
R Hong, B Xu - Cancer communications, 2022 - Wiley Online Library
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …
associated with many risk factors, including genetic and hereditary predisposition. Breast …
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
[HTML][HTML] EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
E Le Rhun, M Guckenberger, M Smits, R Dummer… - Annals of …, 2021 - Elsevier
Highlights•This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours.•The guideline covers clinical and …
patients with brain metastases from solid tumours.•The guideline covers clinical and …
Radiation therapy for brain metastases: an ASTRO clinical practice guideline
Purpose This guideline provides updated evidence-based recommendations addressing
recent developments in the management of patients with brain metastases, including …
recent developments in the management of patients with brain metastases, including …
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial
JM Pérez-García, M Vaz Batista, P Cortez… - Neuro …, 2023 - academic.oup.com
Abstract Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity
in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has …
in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has …
The blood–tumour barrier in cancer biology and therapy
PS Steeg - Nature Reviews Clinical Oncology, 2021 - nature.com
The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …
severely limiting and tightly controlling the ingress of substances into the brain from the …
Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with …
Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
Epidemiology of brain metastases and leptomeningeal disease
N Lamba, PY Wen, AA Aizer - Neuro-oncology, 2021 - academic.oup.com
Brain metastases affect a significant percentage of patients with advanced extracranial
malignancies. Yet, the incidence of brain metastases remains poorly described, largely due …
malignancies. Yet, the incidence of brain metastases remains poorly described, largely due …
Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO guideline update
SH Giordano, MAB Franzoi, S Temin… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …